Market Research Report: LabGenius

Company Overview

Name, Mission of the Company

• Name: LabGenius

• Mission: LabGenius aims to accelerate the discovery of next-generation therapeutic antibodies designed for maximum potential by developing a smart robotic platform (EVA™) capable of designing, conducting, and learning from its own experiments.

Foundation and Founders

• Founded in: 2012

• Founder: James Field (while studying for a PhD in synthetic biology at Imperial College London)

Key People in the Company

• CEO: Dr. James Field

• CTO: Leonard Wossnig

• Chairman: Dr. Edwin Moses

• Board Members include: Dr. Oliver Hardick (M Ventures), Irina Haivas (Atomico), Leila Zegna (Kindred Capital)

Headquarters

• Location: G04 Cocoa Studios, The Biscuit Factory, 100 Drummond Road, London, SE16 4DG, United Kingdom

Number of Employees

• Number of Employees: No information is available

Revenue

• Revenue of the Company: No information is available

Notable Achievements

• LabGenius is known for pioneering the use of machine learning (ML)-driven antibody discovery platforms, particularly in designing novel therapeutic antibodies.

Products

Product Offerings

LabGenius offers platform technology focused on antibody discovery and optimisation:

• Smart Robotic Platform (EVA™): Integrates AI, robotic automation, and synthetic biology to accelerate therapeutic antibody discovery.

High-Level Product Descriptions and Key Features

• EVA™:

• Designs and conducts experiments autonomously.

• Enhances the efficiency of discovering high-performing antibodies by iterating through potential designs using an active learning method known as Multi-Objective Bayesian Optimisation (MOBO).

Platform Applications

• Co-optimises mono- and multi-specific single-domain antibodies.

• Focused on cancer and inflammatory diseases.

• Addresses on-target, off-tumour toxicity in therapeutic antibodies.

Recent Developments

Recent Developments in the Company

• Funding: Raised £35 million in a Series B round led by M Ventures, bringing total funding to £58 million, to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards clinical application.

New Products Launched

• No specific new products are mentioned.

New Features Added to Existing Products

• Platform Enhancement: The platform capability is extended to facilitate broader strategic partnerships across multiple therapeutic modalities, notably due to a successful research collaboration with Sanofi.

New Partnerships

• Partners with large biotech and pharmaceutical companies, leveraging enhanced platform capabilities.

Board Changes

• Oliver Hardick of M Ventures and Oliver Sims of Octopus Ventures joined the Board of Directors to bolster strategic initiatives.

Media Presence and Recognition

• BBC News Coverage: Highlighted LabGenius's harnessing of AI in drug discovery.

• PwC | The Life Sciences Future50: Recognized by PwC for innovative technologies.

• The Bio Report Podcast: Discussed use of generative AI for therapeutic antibodies.

Please refer to LabGenius's official websites and resources for more detailed and updated company insights and technology advancements.